Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis.

Autor: Paganelli F; Hospital de Olhos de Araraquara, Rua Henrique Dall'Acqua 45, Araraquara, São Paulo, CEP 14802-530, Brazil., Cardillo JA, Dare AR, Melo LA Jr, Lucena DR, Silva AA Jr, Oliveira AG, Pizzolitto AC, Lavinsky D, Skaf M, Souza-Filho AA, Höfling-Lima AL, Nguyen QD, Kuppermann BD, Herrero-Vanrell R, Belfort R Jr
Jazyk: angličtina
Zdroj: Expert opinion on drug delivery [Expert Opin Drug Deliv] 2010 Aug; Vol. 7 (8), pp. 955-65.
DOI: 10.1517/17425247.2010.498817
Abstrakt: Importance of the Field: The use of topical agents poses unique and challenging hurdles for drug delivery. Topical steroids effectively control ocular inflammation, but are associated with the well-recognized dilemma of patient compliance. Although administration of topical antimicrobials as prophylaxis is acceptable among ophthalmologists, this common practice has no sound evidence base. Developing a new antimicrobial agent or delivery strategy with enhanced penetration by considering the anatomical and physiological constraints exerted by the barriers of the eye is not a commonly perceived strategy. Exploiting the permeability of the sclera, subconjunctival routes may offer a promising alternative for enhanced drug delivery and tissue targeting.
Area Covered in This Review: Ocular drug delivery strategies were reviewed for ocular inflammation and infections clinically adopted for newer class of antimicrobials, which use a multipronged approach to limit risks of endophthalmitis.
What the Reader Will Gain: The analysis substantiates a new transscleral drug delivery therapeutic approach for cataract surgery.
Take Home Message: A new anti-inflammatory and anti-infective paradigm that frees the patient from the nuisance of topical therapeutics is introduced, opening a large investigative avenue for future improved therapies.
Databáze: MEDLINE